Oramed Pharmaceuticals Inc. (ORMP) Trading Down 2.2%
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s share price was down 2.2% during trading on Monday . The company traded as low as $7.56 and last traded at $7.63, with a volume of 61,560 shares traded. The stock had previously closed at $7.80.
A number of equities research analysts have issued reports on ORMP shares. Aegis reaffirmed a “buy” rating and set a $18.00 target price on shares of Oramed Pharmaceuticals in a research report on Wednesday, May 18th. Rodman & Renshaw reaffirmed a “buy” rating and set a $25.00 target price on shares of Oramed Pharmaceuticals in a research report on Friday, May 13th. Finally, FBR & Co upped their target price on Oramed Pharmaceuticals from $15.00 to $20.00 and gave the stock an “outperform” rating in a research report on Thursday, May 26th. Five equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $22.00.
The firm’s market capitalization is $100.23 million. The firm’s 50 day moving average is $8.07 and its 200-day moving average is $7.80.
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.